21 results about "Neuromuscular Blockade" patented technology

The invention relates to a cucurbituril compound and medical application thereof. Specifically, the invention relates to a compound as shown in a formula (I) and a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the compound and application thereof as a therapeutic agent, especially application in treatment or prevention of proliferative diseases, cardiovascular related diseases or hematologic cancers, use in reversing drug-induced neuromuscular block and / or anesthesia. I) # imgabs0 #

The present disclosure relates to compounds of Formula I:suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

Neuromuscular block characterization techniques are disclosed. A muscle movement measurement device generates, unprompted by impulse stimulation to a subject from an external source, at least one signal representative of muscle movement measurements at at least one location of a body of the subject while the subject is experiencing neuromuscular paralysis caused by biophysiological processes at neuromuscular synapses throughout the body including remote from the at least one location. A processing circuit runs a neuromuscular block analysis module that receives the at least one signal, analyzes the muscle movement measurements embedded in the at least one signal, and determines a degree of neuromuscular blockade associated with the neuromuscular paralysis being experienced by the subject. The processing circuitry further generates, for display via a display device, an indication of the degree of the neuromuscular blockade at each said location on the body.

The invention provides a muscle relaxation antagonist for reversing benzylisoquinoline muscle relaxants, particularly provides a preparation method and application of a safer and more effective muscle relaxation antagonist preparation for reversing benzylisoquinoline muscle relaxants, and more particularly provides a preparation method and application of the muscle relaxation antagonist preparation for reversing benzylisoquinoline muscle relaxants. The invention provides omekasone sodium as a substitute for neostigmine for reversing muscle relaxation of a benzylisoquinoline muscle relaxation drug cisatracurium besylate. In the process of remnant neuromuscular block after muscle relaxation induced by a muscle relaxation agent cisatracurium, the omekasone sodium can replace neostigmine, and the omekasone sodium is remarkably superior to neostigmine in the aspects of heart rate maintenance and the like under the condition that the antagonistic drug effect is maintained to be equivalent. The invention also provides the Omexone sodium and a compound pharmaceutical preparation thereof, the Omexone sodium is prepared into freeze-dried powder injection or injection, and the Omexone sodium is suitable for being applied to preparation of antagonistic muscle relaxation drugs.

A compound suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade is provided. The compound can inhibit the CIC-1 ion channel.

Disclosed herein are methods of reducing muscle contraction in a diaphragm or peripheral muscle(s) of a patient sufficient to permit a surgical procedure. The methods may comprise the step of administering an oxime or pharmaceutically acceptable salt thereof to a subject in need thereof in an amount sufficient to achieve said reduced muscle contraction / neuromuscular blockade. Kits and articles of manufacture comprising a container having a label and a composition are also disclosed.

The present invention relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein preferably inhibit the CIC-1 ion channel.

The present disclosure relates to cucurbituril compounds and their pharmaceutical uses. Specifically, the present disclosure relates to a compound of formula (I) and its pharmaceutically acceptable salts, each of the substituents defined in the specification, a method for preparing the compound, and a pharmaceutical composition containing the compound, as well as its use as a therapeutic agent, particularly in the preparation of a medicament for reversing drug-induced neuromuscular blockade and / or anesthesia in the treatment or prevention of proliferative diseases, cardiovascular-related diseases, or hematological cancers. JPEG2025541968000084.jpg41170

The present invention provides a method and system for monitoring neuromuscular blockade of a patient during a surgical procedure. The system and method utilize a stimulator (115) to provide stimulation (904), such as a train of four (TOF), to the patient's nerves. After such stimulation, the system and method monitor the muscle twitch response (906), and based on the monitored muscle twitch, the system and method create (912) a neuromuscular blockade trend curve (706, 804). The neuromuscular blockade trend curve (706, 804) provides an estimated recovery time (808) for the patient, and provides the estimated recovery time (916) to a clinician. If necessary, the estimated recovery time allows the clinician to modify the patient's treatment to accelerate recovery.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

The present disclosure relates to compounds suitable for treating, improving and / or preventing neuromuscular disorders (including reversing drug-induced neuromuscular blockade). Compounds as defined herein can inhibit ClC-1 ion channels.

The present invention relates to a biquaternary ammonium salt compound having an ultra-short-acting neuromuscular blocking function. In particular, the present invention relates to a compound represented by general formula (I-2), or a stereoisomer thereof, a pharmaceutically acceptable salt or co-crystal thereof, a pharmaceutically acceptable salt or co-crystal of the stereoisomer thereof, a solvate thereof, a prodrug thereof, a deuterated derivative thereof, or a metabolite thereof. The present invention also relates to a pharmaceutical composition containing the compound, a preparation method therefor, and the function and use thereof in neuromuscular blockade. Each substituent in the general formula (I-2) is as defined in the description.

A method for monitoring neuromuscular blockade is provided and includes: determining, based on an ultrasound image sequence of a target muscle in response to N consecutive electrical stimulations at equal intervals, temporal variation information of an architectural parameter of the target muscle, where N is an integer greater than 1; determining, based on the temporal variation information and in response to N consecutive electrical stimulations at equal intervals, a first change amount in the architectural parameter of the target muscle after an Nth electrical stimulation and a second change amount in the architectural parameter after a first electrical stimulation; determining a train-of-N ratio based on a ratio of the first change amount to the second change amount; and determining a degree of neuromuscular blockade based on a value of the train-of-N ratio.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC-1 ion channel.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

Neuromuscular block characterization techniques are disclosed. A muscle movement measurement device generates, unprompted by impulse stimulation to a subject from an external source, at least one signal representative of muscle movement measurements at at least one location of a body of the subject while the subject is experiencing neuromuscular paralysis caused by biophysiological processes at neuromuscular synapses throughout the body including remote from the at least one location. A processing circuit runs a neuromuscular block analysis module that receives the at least one signal, analyzes the muscle movement measurements embedded in the at least one signal, and determines a degree of neuromuscular blockade associated with the neuromuscular paralysis being experienced by the subject. The processing circuitry further generates, for display via a display device, an indication of the degree of the neuromuscular blockade at each said location on the body.

A method, apparatus, and computer program product are provided for generating quantitative neuromuscular blockade assessments. Image data captured from a camera, such as a camera integrated in a mobile device is applied to a computer vision model to generate body part movement data indicating positions of the body parts in a three-dimensional space. Using the movement data, a twitch count or train of four (TOF) ratio is calculated and used to generate a quantitative neuromuscular blockade assessment. A notification is generated and provided via a user interface based on the neuromuscular blockade assessment. The quantitative neuromuscular blockade assessment can indicate a depth of neuromuscular blockade, maintenance of neuromuscular blockade, adequate recovery from neuromuscular blockade, presence of residual blockade, a calculated dosage of a maintenance or reversal agent, or the like.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the ClC-1 ion channel.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

The invention belongs to the technical field of biology, and particularly relates to a recombinant botulinum toxin A chimeric protein and application thereof. The recombinant A-type botulinum toxin chimeric protein is constructed by replacing only a C-terminal receptor binding domain or a whole receptor binding domain in a receptor structural domain on the basis of wild-type BoNT / A. The recombinant botulinum toxin A chimeric protein has substrate cleavage activity equivalent to that of wild toxin in vitro, can be effectively taken in Neuro-2a nerve cells and realize substrate cleavage, shows a significantly reduced toxicity level in animal bodies, and has a good application prospect. Wherein the AAAF chimeric protein has the characteristics of rapid effect taking and short action time, and is suitable for situations requiring short-term intervention of neural activity, such as short-term muscular tension regulation or local injection treatment; the AAFF chimeric protein has relatively long neuromuscular blocking duration and relatively high safety, and is suitable for long-term treatment of chronic nervous system diseases.